Literature DB >> 18625100

Assessment and management of breakthrough pain in cancer patients: current approaches and emerging research.

Neil A Hagen1, Patricia Biondo, Carla Stiles.   

Abstract

Cancer pain is highly prevalent and often severe. Fortunately, most cancer pain can be readily managed, with up to 90% of patients responding well to standard interventions. However, breakthrough cancer pain-brief flares of severe pain superimposed on baseline pain-is common, difficult to manage, and often negatively impacts patients' quality of life. Breakthrough cancer pain is traditionally managed with oral, immediate-release opioids. However, because of its sudden onset and severity, oral opioids often fall short of providing adequate control. Research into novel approaches to pain management has identified several innovative strategies for this difficult cancer pain problem. We describe current approaches to assess, define, characterize, and treat breakthrough cancer pain, and summarize recent clinical research on novel agents, novel routes of drug delivery, and other advances in its management.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625100     DOI: 10.1007/s11916-008-0042-1

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  52 in total

1.  An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study.

Authors:  G Zeppetella
Journal:  J Pain Symptom Manage       Date:  2000-10       Impact factor: 3.612

2.  Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.

Authors:  J T Farrar; J Cleary; R Rauck; M Busch; E Nordbrock
Journal:  J Natl Cancer Inst       Date:  1998-04-15       Impact factor: 13.506

3.  Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

Authors:  P H Coluzzi; L Schwartzberg; J D Conroy; S Charapata; M Gay; M A Busch; J Chavez; J Ashley; D Lebo; M McCracken; R K Portenoy
Journal:  Pain       Date:  2001-03       Impact factor: 6.961

4.  Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.

Authors:  Mark Palangio; Donald W Northfelt; Russell K Portenoy; Daniel Brookoff; Ralph T Doyle; Bruce E Dornseif; Michael C Damask
Journal:  J Pain Symptom Manage       Date:  2002-05       Impact factor: 3.612

5.  Self-administered nitrous oxide for the management of incident pain in terminally ill patients: a blinded case series.

Authors:  Joel L Parlow; Brian Milne; Deborah A Tod; G Ivan Stewart; Jane M Griffiths; Deborah J Dudgeon
Journal:  Palliat Med       Date:  2005-01       Impact factor: 4.762

6.  Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  Daniel B Carr; Leonidas C Goudas; William T Denman; Daniel Brookoff; Peter S Staats; Loralie Brennen; Geoff Green; Randi Albin; Douglas Hamilton; Mark C Rogers; Leonard Firestone; Philip T Lavin; Fred Mermelstein
Journal:  Pain       Date:  2004-03       Impact factor: 6.961

7.  Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study.

Authors:  G Zeppetella
Journal:  Palliat Med       Date:  2001-07       Impact factor: 4.762

8.  Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.

Authors:  Neal E Slatkin; Fang Xie; John Messina; Thalia J Segal
Journal:  J Support Oncol       Date:  2007 Jul-Aug

9.  Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients.

Authors:  J Menten; M Desmedt; D Lossignol; A Mullie
Journal:  Curr Med Res Opin       Date:  2002       Impact factor: 2.580

Review 10.  Management of pain in pancreatic cancer.

Authors:  D Saltzburg; K M Foley
Journal:  Surg Clin North Am       Date:  1989-06       Impact factor: 2.741

View more
  9 in total

1.  Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice.

Authors:  Juan A Virizuela; Yolanda Escobar; Javier Cassinello; Pablo Borrega
Journal:  Clin Transl Oncol       Date:  2012-07       Impact factor: 3.405

2.  [Experiences of cancer patients with breakthrough pain and pharmacological treatments].

Authors:  L Bertram; S Stiel; F Elsner; L Radbruch; A Davies; F Nauck; B Alt-Epping
Journal:  Schmerz       Date:  2010-12       Impact factor: 1.107

3.  [Cancer pain therapy in palliative care patients: knowledge of prehospital emergency physicians in training. Prospective questionnaire-based investigation].

Authors:  C H R Wiese; E K Löffler; J Vormelker; N Meyer; M Taghavi; M Strumpf; S Kazmaier; M Roessler; Y A Zausig; A F Popov; C L Lassen; B M Graf; G G Hanekop
Journal:  Schmerz       Date:  2010-09       Impact factor: 1.107

4.  A fixed inhaled nitrous oxide/oxygen mixture as an analgesic for adult cancer patients with breakthrough pain: study protocol for a randomized controlled trial.

Authors:  Qiang Liu; Yu Wang; Xiang-Jiang Luo; Ning-Ju Wang; Ping Chen; Xin Jin; Guo-Xia Mu; Xiao-Min Chai; Yue-Juan Zhang; Yu-Xiang Li; Jian-Qiang Yu
Journal:  Trials       Date:  2017-01-11       Impact factor: 2.279

5.  SEOM clinical guideline for treatment of cancer pain (2017).

Authors:  C Jara; S Del Barco; C Grávalos; S Hoyos; B Hernández; M Muñoz; T Quintanar; J A Meana; C Rodriguez; R de Las Peñas
Journal:  Clin Transl Oncol       Date:  2017-11-10       Impact factor: 3.405

Review 6.  Cancer Pain Management: Opioid Analgesics, Part 2.

Authors:  Rita J Wickham
Journal:  J Adv Pract Oncol       Date:  2017-09-01

Review 7.  Bibliometric Analysis of Research on the Comorbidity of Cancer and Pain.

Authors:  Cheng-Cheng Wu; Yi-Zu Wang; Hao-Yu Hu; Xue-Qiang Wang
Journal:  J Pain Res       Date:  2021-01-28       Impact factor: 3.133

Review 8.  Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.

Authors:  Furio Zucco; Cesare Bonezzi; Diego Fornasari
Journal:  Adv Ther       Date:  2014-07-09       Impact factor: 3.845

9.  Short Onset and Enhanced Analgesia Following Nasal Administration of Non-Controlled Drugs in Nanovesicular Systems.

Authors:  Elka Touitou; Hiba Natsheh; Shatha Boukeileh; Rania Awad
Journal:  Pharmaceutics       Date:  2021-06-28       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.